“In Surprise Decision, FDA Blocks Crucial Cognitive Claim for Takeda’s Brintellix”


Takeda and Lundbeck had prepared to advertise that their latest antidepressant Brintellix (Vortioxetine) could give patients a cognitive boost and help them think and pay attention. While the FDA agreed that cognitive dysfunction in major depressive disorder is “a legitimate target for drug development,” they did not approve the claims for this drug.

Article →

Support MIA

MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.

Select Payment Method
Personal Info

Credit Card Info
This is a secure SSL encrypted payment.

Billing Details

Donation Total: $20 One Time


  1. What I want to know is how this drug supposedly does this. I suspect that this is another useless “antidepressant” developed to part gullible and sad people from their money. I don’t trust anything that drug companies want to put on the market, not only psychiatric drugs but drugs of any kind. I am truly surprised that the FDA said no to the companies.

    Report comment